Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: March 26, 2009
Event: Entry into a Material Definitive Agreement with Hospira Worldwide, Inc.
Key Financial Metrics
This filing reports a strategic agreement rather than periodic financial results. Consequently, the document does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The agreement establishes a framework for future payments, including development fees and product purchase prices, contingent upon regulatory approvals and the completion of specified activities.
Material Changes and Agreement Terms
- Parties: MediciNova, Inc. and Hospira Worldwide, Inc.
- Subject: Development and Supply Agreement for MN-221, a highly selective ß2-andrenergic receptor agonist.
- Scope: Hospira will provide pre-commercialization manufacturing and manufacture commercial supplies using the ADD-Vantage® drug delivery system.
- Regulatory Status: The Products have not yet obtained FDA or foreign regulatory approval.
- Payment Structure: MediciNova will pay development fees upon completion of activities and specified prices for ordered products once specifications are finalized and approvals obtained.
- Exclusivity: MediciNova must buy Products exclusively from Hospira based on forecasts; Hospira cannot manufacture the Products for other parties.
- Term: The agreement lasts until the tenth anniversary of the first commercial sale, with automatic two-year renewals unless terminated with 12 months' notice.
Guidance, Risks, and Contingencies
Termination Rights: Either party may terminate if regulatory approval is not received by a certain date, upon bankruptcy/insolvency, or if a material breach is not cured within 60 days. MediciNova may terminate if it ceases development; Hospira may terminate if MediciNova waives ongoing obligations.
Exit Costs: Upon termination, MediciNova may be required to purchase undelivered Products from firm orders and reimburse Hospira for equipment return or disposal costs.
Confidentiality: Certain terms of the agreement were omitted from this filing pursuant to a Confidential Treatment Request filed with the SEC.
Investor Verification Checklist
- Verify the specific dates by which regulatory approval must be obtained to avoid automatic termination.
- Review the full text of Exhibit 10.1 (Development and Supply Agreement) to understand omitted financial terms and specific fee structures.
- Assess the current clinical development status of MN-221 to gauge the likelihood of reaching commercial sale milestones.
- Confirm the financial impact of potential termination costs, including equipment reimbursement and purchase of undelivered inventory.